Sarepta Therapeutics - SRPT Stock Forecast, Price & News

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SRPT shares.
View SRPT analyst ratings or view top-rated stocks.

12 Wall Street analysts have issued twelve-month price objectives for Sarepta Therapeutics' shares. Their SRPT share price forecasts range from $90.00 to $182.00. On average, they predict the company's stock price to reach $131.31 in the next year. This suggests a possible upside of 18.8% from the stock's current price.
View analysts price targets for SRPT or view top-rated stocks among Wall Street analysts.

Sarepta Therapeutics' stock was trading at $90.05 at the beginning of 2022. Since then, SRPT shares have increased by 22.8% and is now trading at $110.54.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our SRPT earnings forecast.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced its quarterly earnings results on Wednesday, November, 3rd. The biotechnology company reported ($0.60) earnings per share for the quarter, topping analysts' consensus estimates of ($1.86) by $1.26. The biotechnology company had revenue of $189.41 million for the quarter, compared to analyst estimates of $170.13 million. Sarepta Therapeutics had a negative net margin of 60.66% and a negative trailing twelve-month return on equity of 67.98%. During the same period in the previous year, the company earned ($2.50) earnings per share.

Sarepta Therapeutics updated its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $905.00 million-$920.00 million, compared to the consensus revenue estimate of $899.91 million.

15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS).

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SRPT stock can currently be purchased for approximately $110.54.

Sarepta Therapeutics (NASDAQ:SRPT) has a market capitalization of $9.68 billion and generates $701.89 million in revenue each year. The biotechnology company earns $-418,780,000.00 in net income (profit) each year or ($5.87) on an earnings per share basis.

The company employs 840 workers across the globe.

Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The official website for the company is www.sareptatherapeutics.com. The biotechnology company can be reached via phone at (857) 242-4000, via email at investors@sarepta.com, or via fax at 425-354-5038.